Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sawai to Buy US Generic Maker Upsher-Smith
Japanese generic major Sawai Pharmaceutical will acquire privately-held US peer Upsher-Smith Laboratories for US$1.05 billion, the two companies said on April 20.The transaction is expected to close by the end of June. The deal marks Sawai’s first overseas investment and…
To read the full story
Related Article
- Sawai Group President Says US Biz Exit was Due to Lack of Foresight
February 19, 2024
- Sawai Exits US Biz to Cope with GMP and Supply Issues in Japan
January 18, 2024
- Sawai Shooting for 12.7% Annual Growth for Upsher-Smith: Exec
December 27, 2017
- Sawai’s Upsher-Smith Acquisition Completed
June 2, 2017
- With Upsher-Smith Deal Inked, Sawai Looks to Make US Market Its Second Biz Pillar
April 24, 2017
BUSINESS
- Teijin to Divest Feburic, Bonalon, Other Legacy Brands to LTL
June 18, 2026
- Takeda CEO Pulls in 2.3 Billion Yen in FY2025
June 18, 2026
- Sawai’s Revlimid Generic Gains Additional Lymphoma Indications
June 18, 2026
- Efient AGs Widen Labels to Close Indication Gap
June 18, 2026
- AZ, Kyoto Ink Pact to Promote NCD Prevention, Early Detection
June 18, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…